Entrada Therapeutics (TRDA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.7M

Revenue (quarter)

$898,000.00

Revenue growth (year over year)

−53.95%

Gross profit (trailing twelve months)

$4.7M

Gross margin

100.00%

Net income (trailing twelve months)

−$165.8M

Net income (quarter)

−$42.8M

Net income growth (year over year)

+0.79%

Net margin

−3537.73%

Return on equity

−54.09%

EPS (trailing twelve months)

−$3.96

Book value per share

$5.99

P/E (trailing twelve months)

—

Price to book

0.92

Debt to assets

21.90%

Payout ratio

—

Dividend yield

—

Company profile

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

• Is Entrada Therapeutics (TRDA) profitable?

  No. Entrada Therapeutics reported a net loss of $165.8M over the trailing twelve months.

• How much revenue does Entrada Therapeutics (TRDA) make?

  Entrada Therapeutics generated $4.7M in revenue over the trailing twelve months, down 53.95% year over year.

• How do I buy stock in Entrada Therapeutics (TRDA)?

  TRDA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.